Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (411-420 of 448) with videos related to

Pageof 45
Sort By:
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|November 9, 2023
Heart and systemic sclerosis-findings from a national cohort studyAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.
RMD Open|December 10, 2024
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysisAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Annals of the Rheumatic Diseases|January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Annals of the Rheumatic Diseases|August 17, 2012
TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patientsEugénie Koumakis, Julien Wipff, Philippe Dieudé, et al.
Plos Genetics|July 14, 2011
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosisYannick Allanore, Mohamad Saad, Philippe Dieudé, et al.
Human Mutation|May 4, 2012
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosisChristine P Diggle, David A Parry, Clare V Logan, et al.
Pageof 45

Showing results (411-420 of 448) with videos related to

Sort By:
Pageof 45
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|November 9, 2023
Heart and systemic sclerosis-findings from a national cohort studyAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.
RMD Open|December 10, 2024
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysisAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Annals of the Rheumatic Diseases|January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Annals of the Rheumatic Diseases|August 17, 2012
TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patientsEugénie Koumakis, Julien Wipff, Philippe Dieudé, et al.
Plos Genetics|July 14, 2011
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosisYannick Allanore, Mohamad Saad, Philippe Dieudé, et al.
Human Mutation|May 4, 2012
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosisChristine P Diggle, David A Parry, Clare V Logan, et al.
Pageof 45